A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function

Clinical trial NCT02372084 · COMPLETED

Trial details

NCT number: NCT02372084
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Hepatic Impairment

Start date: 2015-04-21
Primary completion: 2016-05-19
Enrollment: 33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.